Display options
Cite
Shakir FA, Ali T, Bigham AC, et al. Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012;8(5):313-7
Shakir, F. A., Ali, T., Bigham, A. C., Ballard, J. D., Miner, P. B., & Philpott, J. R. (2012). Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease. Gastroenterology & hepatology, 8(5), 313-7.
Shakir, Faiz A, et al. "Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease." Gastroenterology & hepatology vol. 8,5 (2012): 313-7.
Shakir FA, Ali T, Bigham AC, Ballard JD, Miner PB, Philpott JR. Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012 May;8(5):313-7. PMID: 22933861; PMCID: PMC3424425.
Copy Download .nbib Format: NLM
Share it on

Gastroenterol Hepatol (N Y). 2012 May;8(5):313-7.

Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease.

Gastroenterology & hepatology

Faiz A Shakir, Tauseef Ali, Aletha C Bigham, Jimmy D Ballard, Philip B Miner, Jessica R Philpott

Affiliations

  1. Digestive Diseases and Nutrition Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. [email protected]

PMID: 22933861 PMCID: PMC3424425

Abstract

Clostridium difficile infection has increased in prevalence among patients with inflammatory bowel disease (IBD). Serum antibodies against C. difficile toxins have been detected in susceptible populations and may be protective; however, such antibodies have not been previously characterized in IBD patients. This study measured immunoglobulin G antibody levels to C. difficile toxin B in serum from IBD patients in remission and IBD patients in relapse. IBD patients demonstrated significantly higher antibody levels than non-IBD patients. In addition, a higher proportion of IBD patients in remission had positive antibody levels compared to IBD patients in relapse. Further characterization of antibody responses may elucidate understanding of susceptibility to C. difficile infection among IBD patients.

Keywords: Clostridium difficile; Serum; antibodies; inflammatory bowel disease

References

  1. Vaccine. 2010 Jan 22;28(4):965-9 - PubMed
  2. J Exp Med. 1995 Feb 1;181(2):453-61 - PubMed
  3. N Engl J Med. 2000 Feb 10;342(6):390-7 - PubMed
  4. J Med Microbiol. 2008 Jun;57(Pt 6):717-724 - PubMed
  5. Am J Gastroenterol. 2009 May;104(5):1162-9 - PubMed
  6. Gastroenterol Res Pract. 2011;2011:136064 - PubMed
  7. Inflamm Bowel Dis. 2012 Jul;18(7):1340-55 - PubMed
  8. Gut. 2008 Feb;57(2):205-10 - PubMed
  9. J Infect Dis. 1990 Sep;162(3):678-84 - PubMed
  10. Int Immunopharmacol. 2008 Feb;8(2):341-50 - PubMed
  11. Aliment Pharmacol Ther. 2009 Aug;30(3):253-64 - PubMed
  12. Infect Immun. 2009 Nov;77(11):4714-23 - PubMed
  13. Clin Gastroenterol Hepatol. 2007 Mar;5(3):339-44 - PubMed

Publication Types